Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

PDF

Edith Cowan University

Adiponectin

Articles 1 - 3 of 3

Full-Text Articles in Medicine and Health Sciences

Assessing The Causal Effects Of Adipokines On Uric Acid And Gout: A Two-Sample Mendelian Randomization Study, Ruyi Cong, Xiaoyu Zhang, Zihong Song, Shanshan Chen, Guanhua Liu, Yizhi Liu, Xiuyu Pang, Fang Dong, Weijia Xing, Youxin Wang, Xizhu Xu Mar 2022

Assessing The Causal Effects Of Adipokines On Uric Acid And Gout: A Two-Sample Mendelian Randomization Study, Ruyi Cong, Xiaoyu Zhang, Zihong Song, Shanshan Chen, Guanhua Liu, Yizhi Liu, Xiuyu Pang, Fang Dong, Weijia Xing, Youxin Wang, Xizhu Xu

Research outputs 2022 to 2026

Previous observational studies have highlighted associations between adipokines and hyperuricemia, as well as gout, but the causality and direction of these associations are not clear. Therefore, we attempted to assess whether there are causal effects of specific adipokines (such as adiponectin (ADP) and soluble leptin receptors (sOB-R)) on uric acid (UA) or gout in a two-sample Mendelian randomization (MR) analysis, based on summary statistics from large genome-wide association studies. The inverse-variance weighted (IVW) method was performed as the primary analysis. Sensitivity analyses (including MR-Egger regression, weighted median, penalized weighted median, and MR pleiotropy residual sum and outlier methods) were also …


Randomised Placebo-Controlled Cross-Over Study Examining The Role Of Anamorelin In Mesothelioma (The Anthem Study): Rationale And Protocol, Siao Nge Hoon, Katrina Fyfe, Carolyn J. Peddle-Mcintyre, Samantha Bowyer, Felicity Hawkins, Emily Jeffery, Hui Jun Chih, Jenette Creaney, Anna Nowak, Fraser Brims Jan 2020

Randomised Placebo-Controlled Cross-Over Study Examining The Role Of Anamorelin In Mesothelioma (The Anthem Study): Rationale And Protocol, Siao Nge Hoon, Katrina Fyfe, Carolyn J. Peddle-Mcintyre, Samantha Bowyer, Felicity Hawkins, Emily Jeffery, Hui Jun Chih, Jenette Creaney, Anna Nowak, Fraser Brims

Research outputs 2014 to 2021

Introduction Cachexia is common in malignant mesothelioma (MM); half of patients have malnutrition and low skeletal muscle mass. Malnourished patients have worse quality of life (QoL). Weight loss is strongly associated with poor survival. Anamorelin is an oral ghrelin receptor agonist that improves appetite, body weight and QoL in advanced cancer. The aim of this study is to examine the efficacy of anamorelin in improving appendicular skeletal muscle mass (ASM) and patient-reported outcomes in patients with MM with cachexia. Methods and analysis A single-centre, phase II, randomised, placebo-controlled cross-over pilot study with 28-day treatment periods and 3-day washout. Forty patients …


Assessing The Variability And Predictability Of Adipokines (Adiponectin, Leptin, Resistin And Their Ratios) In Non-Obese And Obese Women With Anovulatory Polycystic Ovary Syndrome, Christian Obirikorang, William K. B. A. Owiredu, Sandra Adu-Afram, Emmanuel Acheampong, Evans Adu Asamoah, Enoch Kwabena Antwi-Boasiakoh, Eddie-Williams Owiredu Jan 2019

Assessing The Variability And Predictability Of Adipokines (Adiponectin, Leptin, Resistin And Their Ratios) In Non-Obese And Obese Women With Anovulatory Polycystic Ovary Syndrome, Christian Obirikorang, William K. B. A. Owiredu, Sandra Adu-Afram, Emmanuel Acheampong, Evans Adu Asamoah, Enoch Kwabena Antwi-Boasiakoh, Eddie-Williams Owiredu

Research outputs 2014 to 2021

Objectives

To assess the variability and predictability of adiponectin, leptin, resistin and their ratios in non-obese and obese women with anovulatory polycystic ovary syndrome (aPCOS).

Results

A total of 52 ovulatory controls (mean age = 31.63 ± 4.88 years, BMI = 25.33 ± 2.68 kg/m2); 54 non-obese (mean age = 32.11 ± 4.25 years, BMI = 25.72 ± 2.95 kg/m2) and 50 obese women with aPCOS (mean age = 33.64 ± 4.14 years, BMI = 39.19 ± 2.99 kg/m2) were recruited. The aPCOS group had lower adiponectin [13.0 (10.49–16.59) vs 18.42 (15.72–19.92) µg/ml, p < 0.0001], adiponectin: leptin ratio (A:L) [0.60 (0.35–0.88) vs 1.19 (0.92–1.37), p < 0.0001], and adiponectin: resistin ratio (A:R) [0.30 (0.21–0.43) vs 0.42 (0.32–0.62), p < 0.0001] but a higher leptin [20.02 (14.54–26.80) vs 16.17 (14.51–18.36) ng/ml, p < 0.0001] and leptin: resistin ratio (L:R) [0.53 (0.37–0.82) vs 0.40 (0.27–0.48), p < 0.0001] compared to the controls. The obese aPCOS group had lower adiponectin [11.04 (5.66–13.25) vs 14.18 (11.04–18.02), p < 0.0001 and 18.42 (15.72–19.92) µg/ml, p < 0.0001], A:L [0.36 (0.27–0.44) vs 0.78 (0.61–1.16), p < 0.0001 and 1.19 (0.92–1.37), p < 0.0001], and A:R [0.24 (0.17–0.38) vs 0.40 (0.23–0.58), p < 0.0001 and 0.42 (0.32–0.62), p < 0.0001] but a higher leptin [26.80 (14.28–32.09) vs 17.95 (14.86–21.26), p < 0.05 and 16.17 (14.51–18.36) ng/ml, p < 0.0001] and L:R [0.63 (0.46–1.03) vs 0.41 (0.30–0.61), p < 0.0001 and 0.40 (0.27–0.48), p < 0.0001] compared to the non-obese aPCOS and control group, respectively. A:L showed the best discriminatory power in predicting aPCOS (AUC = 0.83), followed by adiponectin alone (AUC = 0.79), L:R and leptin alone (both AUC = 0.69). Resistin alone had the poorest discriminatory power (AUC = 0.48).